Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/7/2022 | $16.00 → $1.00 | Hold → Sell | Deutsche Bank |
| 6/25/2021 | $21.00 → $12.00 | Neutral → Underweight | JP Morgan |
Deutsche Bank downgraded Rite Aid from Hold to Sell and set a new price target of $1.00 from $16.00 previously
JP Morgan downgraded Rite Aid from Neutral to Underweight and set a new price target of $12.00 from $21.00 previously
Deutsche Bank reiterated coverage of Rite Aid with a rating of Hold and set a new price target of $27.00 from $17.00 previously
In a recent surge of labor unrest, pharmacy employees from CVS Health Corporation (NYSE:CVS) and Walgreens Boots Alliance, Inc. (NASDAQ:WBA) raised their voices by calling out sick or walking out entirely last week. What Happened: These actions were a protest against what they described as insufficient staffing and escalating job demands, which they believed are compromising the safety of their work environment. The grassroots movement, known on social media as "Pharmageddon," is part of a more significant wave of worker activism that has impacted sectors like automotive manufacturing and entertainment. The protests were primarily driven by nonunion workers and have reportedly affected se
Rite Aid Corporation (NYSE:RAD) and drug supplier McKesson Corp (NYSE:MCK) have reached a settlement, securing the continued fulfillment of customer prescriptions throughout Rite Aid's ongoing bankruptcy proceedings. The lawsuit against McKesson alleged that the distributor improperly tried to terminate the drug supply agreement just before Rite Aid's bankruptcy declaration, claiming that McKesson demanded an immediate $700 million payment for outstanding contractual dues. This development emerged shortly after Rite Aid filed for Chapter 11 bankruptcy in New Jersey. Also Read: Privatized Vaccine Distribution Sparks Confusion, Payment Challenges. Citing a court hearing in Trenton, Reute
Secures Interim Approval to Access Up to $3.45 Billion in Debtor-in-Possession FinancingContinues to Serve Customers and Deliver Healthcare Products and Services Across Retail and Online PlatformsRite Aid Corporation (OTC:RADCQ) ("Rite Aid" or the "Company") today announced that it has received approvals from the U.S. Bankruptcy Court for the District of New Jersey for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on October 15, 2023.The Court granted interim approval to access up to $3.45 billion in debtor-in-possession financing from certain of its lenders. This financing is expected to provide sufficient liquidity to support the Company throughout t
Stein Succeeds Elizabeth "Busy" Burr Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced that its Board of Directors has appointed Jeffrey S. Stein as Chief Executive Officer (CEO), Chief Restructuring Officer (CRO) and a member of the Board of Directors, effective immediately. Mr. Stein succeeds Elizabeth ("Busy") Burr, who has served as Interim CEO of Rite Aid since January 2023. Ms. Burr will continue to serve on the Company's Board. Mr. Stein brings more than three decades of experience as a leader and executive director at both public and private companies. Mr. Stein has particular expertise in supporting companies that are driving meaningful business tran
Reaches Agreement in Principle with Key Creditors on the Terms of Financial Restructuring Plan Initiates Voluntary Chapter 11 Process to Implement a Consensual Financial Restructuring That Will Significantly Reduce Debt and Enable Execution of Key Initiatives Receives Commitment for $3.45 Billion in New Financing to Support Business Operations Continuing to Serve Customers and Deliver Healthcare Products and Services Across Retail and Online Platforms Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced it has reached an agreement in principle with certain of its senior secured noteholders on the terms of a financial restructuring plan that will allow the Co
NT 10-Q - RITE AID CORP (0000084129) (Filer)
8-K - RITE AID CORP (0000084129) (Filer)
8-K - RITE AID CORP (0000084129) (Filer)
3 - RITE AID CORP (0000084129) (Issuer)
4 - RITE AID CORP (0000084129) (Issuer)
4 - RITE AID CORP (0000084129) (Issuer)
SC 13G/A - RITE AID CORP (0000084129) (Subject)
SC 13G/A - RITE AID CORP (0000084129) (Subject)
SC 13G/A - RITE AID CORP (0000084129) (Subject)
Expanded personalized population health capabilities support better health journeys for patients Carenet Health, a trusted partner in helping organizations simplify and power the business of healthcare, is excited to announce it is acquiring Health Dialog, a worldwide leader in delivering clinical decision support offerings. This acquisition enables Carenet to leverage its combined platform, analytics and clinicians to deliver greater efficiency and outcomes-based financial performance for clients. Health Dialog provides personalized population health services to health plans, providers, employers and pharmaceutical manufacturers. Carenet is acquiring all assets of Health Dialog from
Secures Interim Approval to Access Up to $3.45 Billion in Debtor-in-Possession Financing Continues to Serve Customers and Deliver Healthcare Products and Services Across Retail and Online Platforms Rite Aid Corporation (OTC:RADCQ) ("Rite Aid" or the "Company") today announced that it has received approvals from the U.S. Bankruptcy Court for the District of New Jersey for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on October 15, 2023. The Court granted interim approval to access up to $3.45 billion in debtor-in-possession financing from certain of its lenders. This financing is expected to provide sufficient liquidity to support the Company th
Stein Succeeds Elizabeth "Busy" Burr Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced that its Board of Directors has appointed Jeffrey S. Stein as Chief Executive Officer (CEO), Chief Restructuring Officer (CRO) and a member of the Board of Directors, effective immediately. Mr. Stein succeeds Elizabeth ("Busy") Burr, who has served as Interim CEO of Rite Aid since January 2023. Ms. Burr will continue to serve on the Company's Board. Mr. Stein brings more than three decades of experience as a leader and executive director at both public and private companies. Mr. Stein has particular expertise in supporting companies that are driving meaningful business tran
Revenues of $5.7 Billion, Compared to Prior Year Revenues of $6.0 Billion Retail Comparable Same Store Prescriptions Increased 4.7 Percent – Comparable Same Store Prescriptions, Excluding COVID Impact, Increased 7.4 Percent Net Loss of $306.7 Million Compared to Prior Year Net Loss of $110.2 Million – Increase Largely Attributable to a Goodwill Impairment Charge at Elixir Adjusted EBITDA of $91.7 Million, Compared to Prior Year Adjusted EBITDA of $100.1 Million Updates Fiscal 2024 Outlook Rite Aid Corporation (NYSE:RAD) today reported operating results for its first fiscal quarter ended June 3, 2023. "Our first quarter results were driven by strong script growth, solid ph
Rite Aid Corporation (NYSE:RAD) will release financial results for its Fiscal 2024 First Quarter, which ended June 3, 2023, on Thursday, June 29, 2023. The company will hold an analyst call at 8:30 a.m. ET with remarks by Rite Aid's management team. The call will be broadcast at https://investors.riteaid.com. The telephone replay will be available beginning at 12:00 p.m. ET on Thursday, June 29, 2023, through 11:59 p.m. ET on July 29, 2023. To access the replay of the call, please dial (800) 770-2030 or (647) 362-9199 and enter the seven-digit reservation number 9029129. The webcast replay of the call will also be available at https://investors.riteaid.com starting at 12 p.m. ET Thursda
Fourth Quarter Highlights: Revenues of $6.1 billion, Comparable to Prior Year Retail Comparable Same Store Prescriptions Increased 5.2 Percent – Comparable Same Store Prescriptions, Excluding COVID Impacts, Increased 9.7 Percent Net Loss per Share of $4.39, Compared to Prior Year Net Loss per Share of $7.18 Adjusted EBITDA of $128.6 million, Compared to the Prior Year Adjusted EBITDA of $106.1 million Completed Tender Offer for $165 million of our 2025 notes – Reducing Amount Outstanding to $320 million From $600 million at Beginning of Fiscal 2022 Full Year Highlights: Revenues of $24.1 billion, Compared to Prior Year Revenues of $24.6 billion Retail Comparable Same